Trial Profile
A Safety and feasibility study of standard dosing day 1 carboplatin AUC 5 every 3rd weeks with daily Navelbine® 20/30mg (oral) during 4 cycles (12 weeks) for the treatment of advanced NSCLC; A feasibility study (Sikkerheds- og effektstudie af standard (st.) dosering af carboplatin dag 1 hver 3. uge plus daglig Navelbine® 20/30 mg (oral) i lØbet af 4 cykler (12 uger) til behandling af fremskreden ikke små-cellet lungekræft; Et pilot studie)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2020
Price :
$35
*
At a glance
- Drugs Vinorelbine (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms NavMetro protocol
- 17 Oct 2020 Status changed from recruiting to completed.
- 13 Mar 2018 New trial record